Managing comorbidities in Covid-19 patients: A drug utilization study in a COVID-dedicated hospital in Northern India
Introduction: In the prevailing COVID-19 pandemic, the Indian healthcare system has worked hard towards restricting the adverse outcomes to the least possible figures. The present study aims to share the experience of a COVID-dedicated tertiary care government hospital in Northern India of managing COVID-19 patients with comorbidities. Methodology: A retrospective, observational study was conducted in a COVID-dedicated tertiary health care government hospital in Northern India. Details on sociodemographic data, hospital admission data, and drug utilization pattern of all laboratory-confirmed COVID-19 patients of all age groups, either gender, having comorbidity (s), and admitted between April and September, 2020 were noted and evaluated. Results: Among the total study participants (N = 406), 2868 drugs were prescribed. Out of these, 2336 were used for the management of symptoms of COVID-19 and 532 were used for the management of coexistent comorbidity (s). For COVID-19 symptoms, the most commonly prescribed class of drugs were antimicrobials (853, 36.52%), followed by nonsteroidal antiinflammatory drugs (374, 16.01%), proton pump inhibitors (299, 12.80%), antihistamines (232, 9.93%), immunosuppressant drugs (103, 4.41%), and others. For comorbidities most commonly prescribed were antihypertensive (310, 58.60%) drugs, followed by antidiabetic drugs (166, 31.38%), bronchodilators (34, 6.43%), thyroid hormones (11, 2.08%), immunosuppressant drugs (7, 1.32%). Conclusion: The most frequently prescribed antihypertensives were calcium channel blockers (CCBs) and least prescribed was beta blocker+CCB. Among the antidiabetic drugs, most frequently prescribed was insulin and least prescribed was DPP-4 inhibitors and Biguanide+DPP-4 inhibitor both..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:10 |
|---|---|
| Enthalten in: |
Journal of Family Medicine and Primary Care - 10(2021), 9, Seite 3387-3394 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Aman Sharma [VerfasserIn] |
|---|
| Links: |
doi.org [kostenfrei] |
|---|
| Themen: |
|---|
| doi: |
10.4103/jfmpc.jfmpc_724_21 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
DOAJ067550673 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | DOAJ067550673 | ||
| 003 | DE-627 | ||
| 005 | 20230309071213.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230228s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.4103/jfmpc.jfmpc_724_21 |2 doi | |
| 035 | |a (DE-627)DOAJ067550673 | ||
| 035 | |a (DE-599)DOAJ4a632fa55f7a4aadb6f3ac45ec101cf5 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 0 | |a Aman Sharma |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Managing comorbidities in Covid-19 patients: A drug utilization study in a COVID-dedicated hospital in Northern India |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Introduction: In the prevailing COVID-19 pandemic, the Indian healthcare system has worked hard towards restricting the adverse outcomes to the least possible figures. The present study aims to share the experience of a COVID-dedicated tertiary care government hospital in Northern India of managing COVID-19 patients with comorbidities. Methodology: A retrospective, observational study was conducted in a COVID-dedicated tertiary health care government hospital in Northern India. Details on sociodemographic data, hospital admission data, and drug utilization pattern of all laboratory-confirmed COVID-19 patients of all age groups, either gender, having comorbidity (s), and admitted between April and September, 2020 were noted and evaluated. Results: Among the total study participants (N = 406), 2868 drugs were prescribed. Out of these, 2336 were used for the management of symptoms of COVID-19 and 532 were used for the management of coexistent comorbidity (s). For COVID-19 symptoms, the most commonly prescribed class of drugs were antimicrobials (853, 36.52%), followed by nonsteroidal antiinflammatory drugs (374, 16.01%), proton pump inhibitors (299, 12.80%), antihistamines (232, 9.93%), immunosuppressant drugs (103, 4.41%), and others. For comorbidities most commonly prescribed were antihypertensive (310, 58.60%) drugs, followed by antidiabetic drugs (166, 31.38%), bronchodilators (34, 6.43%), thyroid hormones (11, 2.08%), immunosuppressant drugs (7, 1.32%). Conclusion: The most frequently prescribed antihypertensives were calcium channel blockers (CCBs) and least prescribed was beta blocker+CCB. Among the antidiabetic drugs, most frequently prescribed was insulin and least prescribed was DPP-4 inhibitors and Biguanide+DPP-4 inhibitor both. | ||
| 650 | 4 | |a co-morbidity | |
| 650 | 4 | |a covid-19 | |
| 650 | 4 | |a drug utilization pattern | |
| 653 | 0 | |a Medicine | |
| 653 | 0 | |a R | |
| 700 | 0 | |a Manish Jain |e verfasserin |4 aut | |
| 700 | 0 | |a Rahul Yadav |e verfasserin |4 aut | |
| 700 | 0 | |a Priyanka Rathi |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i In |t Journal of Family Medicine and Primary Care |d Wolters Kluwer Medknow Publications, 2017 |g 10(2021), 9, Seite 3387-3394 |w (DE-627)DOAJ000094609 |x 22787135 |7 nnns |
| 773 | 1 | 8 | |g volume:10 |g year:2021 |g number:9 |g pages:3387-3394 |
| 856 | 4 | 0 | |u https://doi.org/10.4103/jfmpc.jfmpc_724_21 |z kostenfrei |
| 856 | 4 | 0 | |u https://doaj.org/article/4a632fa55f7a4aadb6f3ac45ec101cf5 |z kostenfrei |
| 856 | 4 | 0 | |u http://www.jfmpc.com/article.asp?issn=2249-4863;year=2021;volume=10;issue=9;spage=3387;epage=3394;aulast=Sharma |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/2249-4863 |y Journal toc |z kostenfrei |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_DOAJ | ||
| 951 | |a AR | ||
| 952 | |d 10 |j 2021 |e 9 |h 3387-3394 | ||